๐ The FDA board has voted to approve gene therapy for Duchenne muscular dystrophy, which is a positive development in the field of gene therapy.
๐ฌ The approval shows progress in the regulatory environment for gene therapy and is expected to benefit the gene therapy sector as a whole.
๐ The approval is anticipated to be finalized on May 29th and will have a significant impact on the field of genetic medicine.
๐ผ The biotech sector has been busy with deal making, with over 70 billion dollars of announced acquisitions so far this year.
๐ The attractive valuation of small and mid-cap biotech companies has led to increased interest from acquirers.
๐ฐ Capital constraints and limited runway have motivated companies with good technology and prospects to seek acquisitions.
๐ The approval of gene therapy for Duchenne muscular dystrophy by the FDA board is a significant development.
๐ฐ Commercially successful companies with approved drugs or potential acquisitions tend to have an easier time securing capital.
๐ฏ Argenx, a later stage company with a successful drug launch, is predicted to be a potential acquisition target.
๐งฌ The FDA has voted to approve a gene therapy for Duchenne muscular dystrophy.
๐ผ Blueprint Medicines, a biotech company, is commercializing a drug called Ava kit and has an important upcoming date for an additional indication.
๐๏ธ An important data for a disease called CIDP is expected to be released in July.
Working With Todoist | Ep 163 | Prioritising The Eisenhower Way
Working With Todoist | Ep 157 | 5 Ways To Get Faster With Todoist
Working With Todoist | Ep 161 | Todoist & Drafts. A Match Made In Heaven!
Tony Robbins on How to Break Your Negative Thinking
''Faรงo MAIS DE 100 MIL Reais Todo Mรชs'' | Higor Neves - Kiwicast #44
DIY Hair Tucking Tutorial | Peekaboo Red Color Long Knotless Braids (Red Bottom Braids)